RESEARCH ARTICLE

CRISPR/Cas9-based editing of a sensitive transcriptional regulatory element to achieve cell type-specific knockdown of the NEMO scaffold protein

Milad Babaei1☯, Yuekun Liu1☯, Shelly M. Wuerzberger-Davis2, Ethan Z. McCaslin1, Christopher J. DiRusso1, Alan T. Yeo1, Larisa Kagermazova1, Shigeki Miyamoto2, Thomas D. Gilmore1* *

1 Department of Biology, Boston University, Boston, Massachusetts, United States of America,  
2 Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, United States of America

☯ These authors contributed equally to this work.

* gilmore@bu.edu

Abstract

The use of alternative promoters for the cell type-specific expression of a given mRNA/protein is a common cell strategy. NEMO is a scaffold protein required for canonical NF-κB signaling. Transcription of the NEMO gene is primarily controlled by two promoters: one (promoter B) drives NEMO transcription in most cell types and the second (promoter D) is largely responsible for NEMO transcription in liver cells. Herein, we have used a CRISPR/Cas9-based approach to disrupt a core sequence element of promoter B, and this genetic editing essentially eliminates expression of NEMO mRNA and protein in 293T human kidney cells. By cell subcloning, we have isolated targeted 293T cell lines that express no detectable NEMO protein, have defined genomic alterations at promoter B, and do not support activation of canonical NF-κB signaling in response to treatment with tumor necrosis factor. Nevertheless, non-canonical NF-κB signaling is intact in these NEMO-deficient cells. Expression of ectopic wild-type NEMO, but not certain human NEMO disease mutants, in the edited cells restores downstream NF-κB signaling in response to tumor necrosis factor. Targeting of the promoter B element does not substantially reduce NEMO expression (from promoter D) in the human SNU-423 liver cancer cell line. Thus, we have created a strategy for selectively eliminating cell type-specific expression from an alternative promoter and have generated 293T cell lines with a functional knockout of NEMO. The implications of these findings for further studies and for therapeutic approaches to target canonical NF-κB signaling are discussed.

Introduction

Much functional gene diversity in humans is generated by the use of alternative splicing and alternative promoters [1, 2]. It is estimated that over 50% of human genes have alternative
splicing and/or use alternative promoters, and alternative promoter usage has also been coupled to alternative splicing [2, 3, 4]. In many cases, alternative promoters are used for the tissue-specific or developmentally timed expression of a given gene, and abnormal alternative splicing or promoter usage has been associated with human disease, especially cancer [2, 5, 6, 7]. For some genes, alternative promoters direct the expression of an identical protein coding region in different cell types or under different conditions by virtue of the promoters being located upstream of distinct 5’ non-translated exons that splice to a common set of downstream coding exons. Methods for assessing the function of tissue-specific alternative promoter usage for individual genes are limited. In this paper, we have used a CRISPR/Cas9-based targeting approach to investigate cell type-specific promoter expression of a key gene (NEMO) in NF-κB signaling.

The mammalian NF-κB transcription factor is involved in the regulation of many cell and organismal processes [8]. NF-κB itself is tightly regulated by subcellular localization: that is, NF-κB is located in the cytoplasm when inactive, and is induced to translocate to the nucleus when activated by upstream signals. In canonical NF-κB signaling, NF-κB is activated by IKKβ-mediated phosphorylation of the NF-κB inhibitor IκB, which is then degraded to allow NF-κB to enter the nucleus. In non-canonical signaling, cytoplasmic NF-κB p100 is phosphorylated by IKKα, an event that induces proteasome-mediated processing of p100 to p52, which then enters the nucleus to affect gene expression [9].

NEMO (NF-κB Essential MODulator) is a protein that serves as a scaffold for IKKβ in canonical NF-κB signaling [10]. In the absence of NEMO, canonical NF-κB signaling cannot be activated [11]. In contrast, activation of non-canonical processing of NF-κB p100 generally does not require NEMO [9]. As such, NEMO is a key regulator for activation of the canonical NF-κB pathway by a variety of upstream signals, and NEMO serves to distinguish activation of canonical and non-canonical NF-κB pathways.

NEMO is also involved in human disease in two prominent ways. First, mutations in the NEMO gene (IKBKG, chromosome X), which generally compromise the ability of NEMO to support activation of NF-κB, lead to a variety of developmental and immunodeficiency diseases in humans [10, 12]. Second, NEMO is required for the constitutive and chronic activation of canonical NF-κB signaling that occurs in a variety of cancers, and is required for the ability of these cancer cells to proliferate or survive (i.e., avoid apoptosis) [10, 13, 14]. Therefore, inhibition of canonical NF-κB signaling can inhibit proliferation or induce apoptosis in a variety of cell- and animal-based cancer models [14]. However, enthusiasm for NF-κB-directed inhibition for cancer therapy was greatly dampened by the finding that systemic and genetic inhibition of canonical NF-κB in animal models leads to liver toxicity and often cancer [15, 16]. For example, mice with liver-specific knockouts of NEMO develop liver damage and sometimes cancer [17, 18].

We had three goals in this research: 1) to demonstrate that CRISPR-based targeting of an alternative promoter can be used to knock down expression of a gene in a tissue-specific manner; 2) to create a NEMO-deficient, highly transfectable human cell line for NEMO protein analysis; and 3) to establish a proof-of-principle concept for targeting the NF-κB signaling pathway for disease intervention in a way that might circumvent unwanted side effects in the liver.

**Results**

**CRISPR-based targeting of a core promoter sequence in Exon 1B of the NEMO gene abolishes NEMO protein expression in HEK 293T cells**

The human IKBKG (NEMO, herein) gene, encoding the NEMO protein, has four alternative 5’ non-coding exons (1D, 1A, 1B, 1C) that direct transcription in a tissue-specific fashion [19] (Fig
Exon 1B is the most commonly used first exon in most cell types [19], and this region has a strong RNA Pol II, H3K4-me3 and DNase hypersensitivity peaks in HEK 293 cells (Fig 1A). Moreover, the exon 1B-containing mRNA is part of the major NEMO transcript found on polysomes in human 293T embryonic kidney cells [20] (see also Fig 1A). Within exon 1B, we noted a sequence (ACCGCGAAACT) that is just downstream of a major transcription start site (TSS) of the NEMO gene, and that is within a consensus sequence that is located near the TSS of many genes [21] (Fig 1A). Based on these cumulative observations, we put forth the hypothesis that this sequence is important for efficient transcription of the NEMO gene in 293T cells.

As a first step in testing that hypothesis, we sought to disrupt the predicted exon 1B core promoter element by CRISPR/Cas9 targeting in 293T cells using lentiviral transduction of Cas9 and a gRNA targeting the identified site. After puromycin selection to create a pool of transduced 293T cells, we performed Western blotting for NEMO. As shown in Fig 2A, the levels of NEMO protein were clearly reduced in two independent pools of cells transduced with the lentivirus containing the targeting gRNA as compared to cells transduced with the same vector containing no gRNA. Equal levels of total protein (as judged by β-tubulin Western blotting) were present in both cell lysates, and the FLAG-tagged Cas9 protein was expressed in all transduced cells (Fig 2A).

In an effort to identify a clone of cells with a total disruption of the targeted sequence, we picked several clones of puromycin-selected cells transduced with the NEMO-targeting lentivirus. Screening of those cell clones by anti-NEMO Western blotting, enabled us to identify a cell clone (clone 1) expressed less than 5% of NEMO protein as compared to the parental, wild-type 293T cells (Fig 2B). A second targeted cell clone (clone 2) had clearly reduced levels of NEMO protein, whereas a clone of 293T cells targeted with a gRNA located downstream of...
exon 1B (clone C, Fig 2B) did not have reduced NEMO protein expression as compared to parental 293T cells.

To characterize the genomic disruptions in clone 1, we used PCR to amplify the region surrounding the gRNA-targeted site and subjected the pooled PCR product to next generation sequencing. We obtained approximately 34,000 sequence reads from the targeted region in clone 1 cells. All of the 34,000 sequence reads from clone 1 cells had disruptions within the predicted gRNA site, and all had disruptions within the consensus core promoter sequence (ACCGCGAAACT). With a cutoff of 0.26% of total reads, we identified 42 genomic disruptions at the targeted site in clone 1 cells (Fig A in S1 File). The major genomic disruption

https://doi.org/10.1371/journal.pone.0222588.g002
(comprising 27.7% of the reads) had a one base pair deletion in the non-variant AAA sequence in the consensus sequence (i.e., `ACCGCGAAACT` to `ACCGCG_AACT`) (Fig 2C). These results make three points: 1) based on the depth of sequencing, there are few, if any, wild-type exon 1B sequences within clone 1; 2) there is genomic heterogeneity at the targeted site within clone 1; and 3) the lack of NEMO protein in clone 1 is likely due to disruption of the targeted sequence, by as little as a 1-bp deletion.

We next compared the expression of NEMO mRNA in wild-type 293T cells and clone 1 cells. First, we used qPCR to compare the total NEMO mRNA in the wild-type and clone 1 cells, by using primer sets downstream of the targeted upstream region, i.e., in exons 2 and 3 or in exons 6 and 7. As shown in Fig 2D, the total NEMO mRNA was reduced by at least 50- to 100-fold in clone 1 cells. Similarly, using primers in exon 1B and in the proximal first intron to detect unspliced NEMO pre-mRNA, we detected an appropriately sized band in RNA from wild-type 293T cells, but no amplified product when using RNA from clone 1 cells (Fig 2E). The levels of control GAPDH mRNA were similar in both cell types (Fig 2E). Thus, the levels of pre- and mature NEMO mRNA are greatly reduced in clone 1 cells, which have a variety of genomic deletions in a consensus exon 1B core promoter genomic sequence, and these disruptions likely account for the lack of NEMO mRNA and consequently NEMO protein expression in clone 1 cells.

**Clone 1 cells are defective for induced activation of NF-κB signaling**

To determine whether the lack of NEMO expression renders clone 1 cells defective for NF-κB signaling, we compared the activation of NF-κB signaling in wild-type and clone 1 cells in response to a variety of agents (TNFα, and DNA-damaging agents camptothecin, VP16, doxorubicin, and gamma irradiation). As shown in Fig 3A, clone 1 cells did not show increased nuclear NF-κB DNA-binding activity in response to any of these agents, whereas control 293T cells showed robust induction of nuclear NF-κB DNA-binding activity. Moreover, induced phosphorylation of IκBα was not detected in clone 1 cells in response to any of these agents (Fig 3A), but was seen in control 293T cells. As controls, we show that tubulin expression andOct DNA-binding activity are similar in wild-type and clone 1 cells, under all conditions (Fig 3A).

To confirm that the lack of responsiveness of clone 1 cells to NF-κB-activating agents was solely due to the loss of NEMO expression, we transfected clone 1 cells with an expression vector for FLAG-NEMO (which lacks the 5’ exon 1B sequences and is therefore not susceptible to gRNA targeting), and then treated the cells with TNFα. As shown in Fig 3B, re-expression of wild-type NEMO in clone 1 cells restored TNFα-induced phosphorylation of IκBα as well as nuclear translocation of NF-κB subunit p65. Re-expression of NEMO proteins with mutations that are found in some human disease patients has variable abilities to restore TNFα-induced phosphorylation of IκBα: mutants D113N, R123W, and Q183H were not statistically different than wild-type NEMO, whereas mutants L153R, R173G and R175P had statistically reduced activity as compared to wild-type NEMO (Fig 3C). Consistent with our previous results [22], expression of a NEMO mutant (9-SG) with an insertion in a core domain of NEMO did not restore TNFα-induced phosphorylation of IκBα (Fig 3C). Taken together, these results indicate that clone 1 cells are specifically defective for stimulus-based activation of canonical NF-κB signaling, and that TNFα-induced activation of NF-κB signaling in clone 1 cells can be restored by re-expression of wild-type NEMO.

**Reduced genomic heterogeneity in a subclone of clone 1 cells**

Because of the heterogeneity of CRISPR/Cas9-directed genomic deletions at the NEMO core promoter site in clone 1 cells, we sought to isolate a cell clone with a reduced number of
genomic disruptions at the targeted site. Therefore, we made cell subclones by plating clone 1 cells at less than one cell per well. Five such cell subclones were then expanded and analyzed. Like parental clone 1 cells, all subclones expressed no detectable NEMO protein (Fig 4A). Preliminary sequence analysis indicated that clone 1.1 had the least genomic complexity around the targeted site, and so clone 1.1 was primarily selected for further analysis. As shown in Fig 4B, analysis of ~16,000 sequence reads of a PCR product covering the genomic disruption of

![Figure 3](https://doi.org/10.1371/journal.pone.0222588.g003)
Clone 1.1 cells showed that over 99% of the reads contained an 8-bp deletion at the targeted site (and about 0.9% of the reads had a 1-bp deletion of an A residue in the triplet of the consensus sequence, i.e., ACCGCG–A ACT). A second subclone (clone 1.3) had over 80% of its total reads (9,485) showing a 2-bp deletion in the AAA stretch of the consensus sequence (ACCGCG__ACT). As a second method of confirming the genomic editing at the target site in

**Fig 4. Isolation of cell subclones from clone 1 cells.** (A) Five subclones of clone 1 cells were isolated and analyzed by Western blotting for NEMO. Shown also are control 293T and clone 1 cell extracts. (B) CRISPR sequencing of the PCR-amplified exon 1B core promoter in clones 1.1 and 1.3 was used to characterize the genomic disruptions (as done for Fig 2C). (C) PCR-amplified exon 1B core promoter from WT 293T and clone 1.1 genomic DNA was analyzed as Uncut or BsiEI-digested DNA. DNA was electrophoresed on a 1.5% agarose gel and detected with ethidium bromide. (D) Clone 1.1 and 1.3 cells were transfected with pcDNA-FLAG or pcDNA-FLAG-NEMO. Two days later, cells were treated with TNFα (+, 20 ng/ml for 10 min) or were left untreated (−). Whole-cell extracts were analyzed for phospho-IκBα or NEMO expression. (E) Control 293T cells and clone 1.1 cells were transfected with pcDNA vector control or pcDNA-HA-NIK. Whole-cell extracts were subjected to Western blotting for HA-NIK, NEMO, and p100/p52. (F) Control 293T cells and clone 1.1 cell extracts were analyzed by Western blotting for FLAG-Cas9 (anti-FLAG). (G) Control 293T cells and clone 1.1 cell extracts were analyzed by Western blotting for G6PD and NEMO. Where indicated, Ponceau staining of the filters was done to ensure approximately equal loading of total protein.

https://doi.org/10.1371/journal.pone.0222588.g004
clone 1.1 cells, we used PCR amplification of the targeted site followed by restriction digestion with BsiEI, as there is a BsiEI restriction enzyme site at the wild-type target sequence (see Fig B in S1 File) that would be destroyed by the 8-bp deletion in clone 1.1 genomic DNA. As predicted, the PCR product amplified from control 293T cell genomic DNA was digested by BsiEI, but the PCR product from clone 1.1 cell genomic DNA was not digested by BsiEI (Fig 4C).

To characterize further the 1.1 and 1.3 cell subclones, we first assessed whether IκBα was phosphorylated in these cells in response to TNFα. As shown in Fig 4D, 1.1 and 1.3 cells transfected with an empty vector did not show phosphorylation of IκBα following treatment with TNFα, whereas clone 1.1 and 1.3 cells transfected with a NEMO expression vector showed readily detectable TNFα-induced phosphorylation of IκBα.

Activation of non-canonical NF-κB signaling, which occurs by IKKα-directed phosphorylation and processing of NF-κB p100, has generally been found to be independent of NEMO [9]. Consistent with these findings, overexpression of NIK, an activator of non-canonical NF-κB signaling, led to equal levels of NF-κB p100 processing to p52 in both wild-type 293T and clone 1.1 cells (Fig 4E). Of note, the FLAG-Cas9 protein is still expressed in clone 1.1 cells, even after subcloning and extensive passaging (Fig 4F).

Expression of G6PD from the bi-directional promoter is not affected in clone 1.1 cells

The NEMO exon 1B promoter is a bi-directional GC-rich (TATA box-lacking) promoter [23, 24]. That is, on the opposite DNA strand in the opposite direction, there are multiple start sites for transcription of the G6PD gene [25]. Western blotting showed that expression of glucose-6-phosphate 1-dehydrogenase protein is not altered in clone 1.1 cells as compared to control cells (Fig 4G). Therefore, the 8-bp deletion in clone 1.1 cells is unlikely to have an effect on G6PD transcription, indicating that the 8-bp deletion inactivates the bi-directional promoter only for NEMO expression.

Treatment of 293T cells with the core element gRNA and dCas9 also reduces NEMO expression

Based on the above experiments, we reasoned that other methods of targeting the exon 1B region might result in reduced NEMO expression. In particular, targeting of genomic regions with dCas9, which has mutations in its catalytic residues required for DNA-cleaving activity, has been shown to block specific gene expression under some conditions [26, 27]. Therefore, we first created a version of pLenti-CRISPR2.0 in which Cas9 was mutated at residues 10 and 840 (D10G and H840A), which inactivates the DNA cleaving function of Cas9 [28]. As above, we then selected 293T cells that had been transduced with the pLenti-CRISPR2.0-dCas9 vector containing the NEMO exon 1B gRNA. We then measured NEMO expression by Western blotting in pools and clones of puromycin-selected cells. As shown in Fig 5A, NEMO expression was reduced in two of three pLenti-CRISPR2.0-dCas9 cell clones containing the exon 1B gRNA and in a pool of transduced cells, as compared to the uninfected control 293T cells. As a control, no NEMO protein was detected in a lysate from clone 1.1 cells (Fig 5A). The extent of NEMO protein knockdown in the pool of CRISPR2.0-dCas9 cells containing the NEMO exon 1B gRNA was similar to that seen in cells with the exon 1B gRNA and wild-type Cas9 (compare Figs 5A–2A). As a further control, we show that the dCas9 protein was expressed in cell clones d2 and d3. Moreover, no dCas9 protein was expressed in clone d1, likely explaining why there was no reduction in NEMO protein in those cells (Fig 5A). In addition, G6PD protein expression was not affected in clones or pools of cells with reduced NEMO protein from dCas9/
gRNA transduction (Fig 5B). Finally, we sequenced the gRNA target site in the genomic DNA from clones d2 and d3. As expected, none of the amplified products for clones d2 and d3 (0 out of 47,208, and 23,507, respectively; Table A in S1 File) had genomic alterations at the target site, indicating that the dCas9 protein expressed in these clones is defective for genome editing. Taken together, the results in this section indicate that occupation of the NEMO exon 1B core promoter target site by the gRNA-dCas9 complex blocks efficient transcription of NEMO in 293T cells.

CRISPR/Cas9 targeting of the NEMO exon 1B core promoter element does not abolish NEMO expression in a human liver cell line

Fusco et al. [19] reported that the exon 1D promoter is the major promoter used for NEMO transcription in liver cells, with approximately 14-fold higher expression of mRNA from exon 1D than exon 1B in both adult human liver tissue and the HepG2 liver cell line. Therefore, we hypothesized that CRISPR-Cas9-based targeting of the exon 1B core promoter sequence would not substantially affect NEMO expression in liver cells. To test this hypothesis, we infected SNU-
423 human liver cells with our pLenti-Crispr2.0 gRNA-containing vector and selected cells with puromycin. As shown in Fig 6A, a puromycin-resistant clone of SNU-423 cells (clone L1) transduced with the gRNA vector expressed levels of NEMO protein that were essentially the same as the parental SNU-423 cells. As a control, we show that the clone L1 cells expressed Cas9 (Fig 6A). In addition, BseE1 digestion of the targeted site in the L1 clone (Fig 6B) and DNA sequencing of the targeted locus in exon 1B showed that approximately 96% of the ~82,000 sequence reads were disrupted by genome editing (Fig 6C). qPCR showed that clone L1 cells expressed approximately 60–80% of the levels NEMO mRNA as parental SNU-423 cells (Fig 6D). Western blots of an additional four Lenti-Crispr2.0 gRNA-containing vector SNU-423 cell clones showed that they expressed approximately similar amounts of NEMO as compared to control cells (Fig C in S1 File). Overall, these results indicate that targeting of the NEMO exon 1B promoter does not substantially affect usage of the upstream liver-specific NEMO promoter 1D, and thus, does not dramatically reduce NEMO protein expression in a human liver cell line.

Discussion

In this paper, we show that CRISPR-based targeting of a core promoter region of the most commonly used promoter of the NEMO gene can efficiently knockdown NEMO protein.

![Fig 6. Targeting of the NEMO exon 1B core promoter with CRISPR/Cas9 does not affect NEMO expression in liver cells.](https://doi.org/10.1371/journal.pone.0222588.g006)
expression and function in human HEK 293T cells. Moreover, targeting of this core promoter sequence only marginally affects NEMO expression in a human liver cell line, in which NEMO transcription is controlled by a distinct liver-specific promoter. Although other researchers have targeted gene regulatory regions by CRISPR-based screening (e.g., [29]), to our knowledge, this is the first use of CRISPR-based genetic editing to ablate expression of an individual gene in a cell type-specific manner.

Transcription of the NEMO gene in the majority of cell types is controlled by a GC-rich, bi-directional promoter (promoter B) that has multiple transcriptional start sites [24], as is commonly found with GC-rich promoters [30]. The gRNA that we used to knockdown NEMO expression in 293T cells targets exon 1B core promoter sequences that are just downstream of a major NEMO TSS. Of note, this gRNA covers a sequence (ACCGCGAAACT) that is similar to one of four consensus sequences found near, and often downstream of, many eukaryotic/human TSSs [21] (Fig 1A). This sequence is likely to be important for the initiation of transcription due to binding of a basal transcription protein or complex [21, 30]. Consistent with the core sequence in the exon 1B promoter being a binding site for a transcription complex, we also found that targeting of dCas9 to this element blocks NEMO protein expression (Fig 5).

Although the consensus sequence logo for this 11-bp common promoter element is quite variable (Fig 1A), it has three invariable A residues. Of note, all 42 of the genomic deletions in our initial 293T cell clone 1 have disruptions in this AAA sequence, including ~28% of the sequence reads that lack only a single A residue. Given that NEMO mRNA levels were reduced by at least 50-fold in clone 1 cells (Fig 2D) and NEMO protein was essentially undetectable (Fig 3A), it is unlikely that there is any substantial NEMO mRNA expression from the ~28% of NEMO alleles that have the 1-bp deletion in the clone 1 population. Moreover, approximately 90% of the edited alleles in clone 1.3 cells had 1 or 2 bp deletions in the AAA sequence (Fig 4B) and expressed no detectable NEMO protein (Fig 4A). Thus, deletion of a single A residue in this core promoter element is likely sufficient to ablate NEMO expression. Similar to our results, Han et al. [31] showed that small CRISPR-based alterations in a gene regulatory element were sufficient to substantially knockdown expression of the Cnn1 gene in mice.

The deletions in exon 1B that affect NEMO expression in 293T cells do not affect expression of the adjacent G6PD promoter, based on the normal levels of G6PD protein expression in clone 1.1 cells (Fig 4G). Franzè et al. [25] mapped core elements (e.g., Sp family TF binding sites, TATA box, TSS, and initiator sequence) required for G6PD transcription. The 5’ end of this G6PD promoter core element region is located approximately 675 bp away from our gRNA target (Fig D in S1 File), likely explaining why the NEMO promoter deletions do not affect G6PD expression.

The clone 1 cells were established from a cell clone that was generated on the first transduction step, and yet clone 1 cells had a highly diverse set of at least 42 disruptions at the target site (Fig A in S1 File). We believe that the target site heterogeneity within this “clone” arose from at least two sources: 1) that not all NEMO alleles were targeted in the originally transduced cell and therefore, additional disruptions occurred after the first cell division; and 2) that some early arising targeted alleles underwent further editing after the first targeting effect (e.g., a 1-bp deletion could have been further edited to an 8-bp deletion), since these cells stably express the NEMO gRNA and Cas9. In contrast, the subclone 1.1 cells were isolated some time after passage of the original clone 1 cells, and thus their NEMO alleles (and the 8-bp deletion) were likely stabilized in the targeted cells.

The NEMO gene is located on the X chromosome. 293-derived cell lines, including 293T, have been reported to have unstable genomes, which can be affected by selection and even freeze-thawing [32, 33]. Different 293 cell lines have been reported to have one to three X chromosomes [32, 33]. FISH analysis showed that our parental and clone 1.1 293T cells also have...
variable numbers of X chromosomes, with the majority of cells having three X chromosomes, and a lesser number having two X chromosomes (Table D in S1 File). Nevertheless, because chromosomes in 293 cells are highly variable in both number and internal gene architecture (even often containing inter-chromosome exchanges) [33] and because our FISH analysis only measures the bulk of X chromosomes, we do not know the precise number of NEMO loci in our 293T cells or derivatives thereof. The nearly homogeneous editing that we see in clone 1.1 cells would be explained most easily by there being a single NEMO locus or a single disrupted locus that was duplicated. In any event, the clone 1.1 cells (derived from the clone 1 cells) represent a nearly homogenous NEMO gene-edited cell line that will likely be useful for researchers who seek to investigate NEMO protein function.

One common method to analyze NEMO mutant function is to re-express the NEMO protein in mouse NEMO knockout cells [34, 35]. Such experiments have two limitations: 1) human NEMO proteins are being analyzed in mouse cells, and 2) to establish pure, selected populations of NEMO reconstituted cells can take a month or more. The 1.1 cell line, which has a nearly homogenous and defined 8-bp deletion in exon 1B (Fig 4B), appears to be useful for the rapid analysis of NEMO mutants, as occur in human disease or as created in the lab. In an experiment that takes less than a week, we show that transient transfection of 1.1 cells with FLAG-NEMO can restore TNFα-induced phosphorylation of IκBα (Fig 4D). Moreover, the ability of transfected NEMO mutants to support TNFα-induced phosphorylation of IκBα was consistent with their reported activities from previous papers. That is, mutants 9-SG, L153R, R173G, and R175P showed limited activity in 1.1 cells and in previous reports [22, 36, 37, 38], whereas mutants D113N, R123W, and Q183H were nearly as active as wild-type NEMO in both 1.1 cells and previous reports [39].

Many cancers rely on canonical NF-κB signaling for growth and survival [14]. Almost all approaches that have sought to target NF-κB function have been directed at NF-κB pathway protein targets [40]. The limitations of such protein-based approaches is that, without an efficient organ-specific delivery system, one will affect the NF-κB in non-cancer cells. In particular, such NF-κB-direct approaches have often resulted in liver toxicity because targeting of NF-κB signaling, and even disruption of NEMO itself, causes liver toxicity [15, 16, 18]. Our finding that gRNA-directed targeting of NEMO promoter B does not substantially affect liver-specific (promoter D) expression of NEMO (Fig 6) suggests that targeting of the core promoter B sequence for the treatment of cancers that rely on canonical NF-κB signaling would not affect liver function in vivo. Precisely how one would target NEMO promoter B in vivo with CRISPR/Cas9 is not obvious; however, it is worth noting that several gRNA/Cas9 in vivo delivery systems have been investigated [41, 42]. Of note, a CRISPR-based screen found NEMO to be among the top 7% of targets for B-cell lymphoma [43], and lymphoid cells do use promoter B for expression of NEMO [19]. Nevertheless, as with all CRISPR-based targeting approaches, the risk of off-target effects is relevant.

Conclusions

In this paper, we have used CRISPR-based genome editing to create small alterations in a previously unknown transcriptional regulatory element that controls tissue-specific expression of the NEMO gene, which encodes a key protein in NF-κB signal transduction. These genomic alterations essentially abolish NEMO mRNA and protein expression in the commonly used 293T human kidney-derived cell line, but do not affect NEMO gene expression in a human liver cell line. Thus, our results show that tissue-specific transcription of gene expression can be effected by precise targeting of an alternative promoter element. Overall, we believe the methods, results, and cell lines generated in this paper will be of interest to others studying NEMO function, and
provide proof-of-principle methods for targeting gene transcription (possibly for therapeutic purposes) and for investigating in vivo effects of alternative promoter usage.

**Materials and methods**

**Cell culture and plasmids**

Human embryonic kidney 293T (HEK 293T) and SNU-423 cells (a gift of Ulla Hansen, Boston University) were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher) with 10% Fetal Bovine Serum (FBS; Biologos), supplemented with 50 U/ml penicillin, and 50 μg/ml streptomycin) at 37˚C, 5% CO₂, in a humidified incubator.

Detailed descriptions of all plasmids and primers used in this paper are presented in Tables B and C in S1 File. Plasmids pcDNA-FLAG and pcDNA-FLAG-NEMO have been described previously [44]. Other pcDNA-FLAG mutants of NEMO are described in Table B of S1 File. pLentiCRISPRv2.0 is from Addgene (plasmid #52961; [45]). The gRNA sequences targeting the NEMO exon 1B core promoter (quality score = 96; 39 off-target sites; crispr.mit.edu) or a control sequence (labelled C in Fig 2B) slightly downstream of the exon 1B site (Table C of S1 File) were synthesized with overhangs and were ligated into BsmBI-digested plenti-CRISPRv2.0. pLentiCRISPRv2.0-dCas9 plasmid was constructed using PCR site-directed overlap mutagenesis in two steps: first, both D10G, and H840A mutations were introduced via amplification with overlapping primers spanning the N, and C-terminal halves of dCas9, the resulting two fragments containing the N- and C-terminal halves of dCas9 were subcloned stepwise into a pSL1180 carrier plasmid. Finally, full-length dCas9 was then subcloned into the LentiCRISPR v2.0 plasmid, and confirmed by DNA sequencing. The relevant portions of plentiCRISPRv2.0-gRNA and pLentiCRISPRv2-dCas9 plasmids containing inserts were also verified by DNA sequencing.

**Establishment of CRISPR NEMO targeted cell lines**

293T cells were seeded at ~60% confluence in a 100-mm tissue culture plates approximately 24 h prior to transfection. The next day, cells were co-transfected with 1 μg plentiCRISPR v2, 2 μg pCMV-dR8.91, and 4 μg pCMV-VSV-G along with 32 μg polyethylenimine (PEI) in a 1 ml serum-free DMEM, and incubated for 15 min at room temperature. The PEI:DNA containing transfection mixture was diluted to 10 ml with DMEM/10% FBS, added to plates of 293T cells, and incubated overnight for approximately 16 h. On the next day, plates were washed once with PBS, and fluid changed with fresh DMEM/10% FBS. Cells were then incubated for two more days, and at that time, transfected cells were subcultured into new 100-mm plates with 10 ml DMEM/10% FBS. The following day, puromycin was added to a final concentration of 2.5 μg/ml. Plates were maintained under puromycin selection, and fluid changed approximately every 3–5 days, until distinct colonies had formed (at approximately 15 days after start of puromycin selection). Cell lines were established from single puromycin-resistant, and were screened for NEMO expression by Western Blotting (e.g., clone 1). After approximately eight passages, subclones of clone 1 cells were isolated by limiting dilution. That is, clone 1 cells were plated in a 96-well tissue culture plate at a density of 0.25 cells/well, and clones (e.g., clones 1.1–1.5) growing out of individual wells were re-screened for NEMO expression by Western blotting.

**Western blotting**

Western blotting was performed essentially as described previously [35, 44]. Whole-cell extracts were prepared in AT lysis buffer (20 mM HEPES pH7.9, 150 mM NaCl, 1mM EDTA,
1 mM EGTA, 20% w/v glycerol, 1% v/v Triton X-100, and Roche Complete Protease Inhibitor). Extracts were then separated on a 10% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane in transfer buffer (20 mM Tris, 150 mM glycine, 20% methanol) overnight at 4˚C. To detect high molecular weight Cas9 and dCas9 proteins, whole-cell extracts were resolved on a 7.5% SDS-polyacrylamide gel, and transferred to nitrocellulose in low-methanol transfer buffer (20 mM Tris, 150 mM glycine, 20% methanol) at 250 mA for 1 h, followed by 170 mA overnight under 4˚C. Membranes were blocked in TMT (10 mM Tris-HCl pH7.4, 150 mM NaCl, 0.1% w/v Tween 20, 5% w/v Carnation nonfat dry milk) for 1 h at room temperature, incubated in the appropriate primary antibody overnight at 4˚C as follows: anti-NEMO (1:1000; #2689, Cell Signaling Technology), anti-phospho-IκBα (1:1000; #9246, Cell Signaling Technology), anti-FLAG (1:1000; #2368, Cell Signaling Technology), anti-HA (1:500; Y-11, Santa Cruz Biotechnology), anti-NF-κB p100/p52 (1:500; #4882, Cell Signaling Technology), anti-p65 (1:2000, #1226 gift of Nancy Rice), anti-tubulin (1:500), anti-G6PD (1:500, #12263, Cell Signaling Technology), and anti-Cas9-HRP (1:10,000; ab202580, Abcam). Membranes were washed four times with TBST (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% w/v Tween 20). Membranes were then incubated with the appropriate secondary HRP-linked antibody as follows: anti-rabbit-HRP (1:3000, Cell Signaling Technology) for NEMO, FLAG, Tubulin, p65, and G6PD or anti-mouse-HRP (1:3000, Cell Signaling Technology) for anti-phospho-IκBα. Membranes were then washed three times with TBST, twice with TBS (10 mM Tris-HCl pH 7.4, 150 mM NaCl), and incubated for 5 min at room temperature with chemiluminescent HRP substrate (SuperSignal West Dura Extended Duration Substrate, Thermo Fisher). Immunoreactive bands were detected by exposing membranes to autoradiography film (GeneMate Blue Basic Autoradiography Film, BioExpress).

**Genomic DNA amplification and analysis**

Genomic DNA was isolated from cultured cells by first lysing the cells in a buffer consisting of 10 mM Tris-HCl, pH 8, 100 mM NaCl, 25 mM EDTA, 0.5% SDS, 1 mg/ml proteinase K. Samples were then heated for 2 h at 60˚C, extracted with phenol twice and with chloroform once. DNA was precipitated with 100% ethanol for 30 min. Approximately 0.5 µg of genomic DNA was used in PCRs. For DNA sequence analysis of the targeted site, DNA was amplified by standard PCR using primers NEMO gExon 1B Fwd and NEMO gIntron 1 Rev (see Table C in S1 File). The PCR product was purified and then sent out for Next-Generation sequencing (MGH CCIB DNA Core). For restriction enzyme analysis of the edited site, DNA was amplified by standard PCR using primers gDNA Fwd and gDNA Rev (Table C in S1 File). From a 50 µl reaction, 7 µl was then digested with BsiEI (New England Biolabs) and analyzed by agarose gel electrophoresis followed by staining with ethidium bromide.

**RNA analysis by RT-PCR and qPCR**

mRNA was isolated from cultured cells using TRIzol RNA purification kit (Qiagen) according to the manufacturer’s instructions. cDNA was synthesized using random primers and M-MLV reverse transcriptase or the TaqMan cDNA synthesis kit (Thermo Fisher). For RT-PCR, NEMO cDNA was amplified by PCR for 32 cycles (using primers NEMO Exon 1B Fwd NEMO Intron 1 Rev [Table C in S1 File]), and DNA was then analyzed by polyacrylamide gel electrophoresis and staining with ethidium bromide. For qPCR, NEMO cDNA was amplified (using primers NEMO Exon 2 Fwd and NEMO Exon 3 Rev or NEMO Exon 6 Fwd and NEMO Exon 7 Rev) using SYBR Green Real-Time PCR kit (Thermo Fisher), and analyzed on an ABI 7900ht qPCR machine. The delta delta CT method was used to quantify the relative fold change in gene expression, and values were normalized to NEMO mRNA expression in
control 293T or SNU-423 cells. For RT-PCR and qPCR GAPDH mRNA was used as a control (see primers in Table C in S1 File).

**Cell treatments**

For analyzing activation of NF-κB by EMSA, 293T and clone 1 cells were treated with various NF-κB inducers (10 ng/ml TNFα for 30 min; 10 μM camptothecin for 2 h; 10 μM VP16 for 2 h; 25 μM doxorubicin for 2 h; 5 Gy of ionizing irradiation and terminated after 1.5 h. A JL Shepard model JL-10 with a cesium (137CS) source was used for gamma-irradiation. Whole-cell extracts were made using total extract (TOTEX) buffer (20 mM HEPES (pH 7.9), 350 mM NaCl, 1 mM MgCl₂, 0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM DTT, 20% glycerol, and 1% NP-40). EMSAs and immunoblotting were performed as described previously [46, 47] and below. In Fig 3A, the following antisera were used: anti-NEMO (FL-419; sc-8330 antibody; Santa Cruz) and anti-tubulin (CP06; EMD Millipore).

For analyzing induced phosphorylation of IκBα, wild-type or CRISPR-edited 293T cells were treated with 20 ng/ml TNFα for 10 min, as described previously [35].

**NEMO reconstitution experiments**

NEMO knockout cells (clone 1, 1.1 or 1.3) were seeded at ~60% in a 60-mm tissue culture plates one day prior to transfecting with pcDNA-FLAG empty vector, pcDNA-FLAG-NEMO, or various pcDNA-FLAG-NEMO mutant vectors (see Fig 3C and Table B in S1 File). Transfections were performed using Effectene Transfection Kit (Qiagen) as follows: 0.2 μg plasmid, and 1.6 μl Enhancer were diluted to a final volume of 32 μl with EC Buffer, and incubated for 5 min at room temperature for DNA condensation. Then, 2 μl Effectene was added, and samples were incubated for 7 min at room temperature to form Effectene-DNA complexes. The final transfection mixture was brought to 1.8 ml with DMEM/10% FBS, added to 60-mm plates containing 3.2 ml of fresh medium, and incubated overnight. Upon reaching confluence (2 days), transfected plates were subcultured into new plates at ~60% density, and incubated again until cells reached confluence (2 days). Cells were then stimulated with 20 ng/ml recombinant TNFα (R&D Systems) for 10 min. Cells were then lysed on ice and processed for Western blotting as described above.

For assessing NEMO mutant activity in clone 1.1 cells, Western blot band intensities for NEMO and phospho-IκBα in control and TNFα-treated cells were quantified using ImageJ. Phosphorylation of IκBα was expressed as a ratio of the phospho-IκBα signal to the NEMO signal for each lysate. Fold change of phospho-IκBα signal from untreated to TNFα-treated cells was calculated and expressed as a percentage of the fold change seen with wild-type NEMO-transfected cells (in the same experiment). Each experiment contained biological triplicates of each mutant, as well as wild-type and empty vector controls. Raw values for band intensities were compared within the same blot, and fold change was used to compare the relative phosphorylation of IκBα between experiments. Significance was assessed with a Student’s t-test.

**Nuclear extract preparation**

To prepare nuclear fractions, control or TNFα-treated (20 ng/ml, for 10 min) cells were resuspended in 400 μl hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl₂, 10 mM KCl), and were incubated on ice for 10 min. Samples were then supplemented with 55 μl NP-40, vortexed for 10 sec, and pelleted at 500 x g for 5 min at 4°C. The nuclear pellet was washed with the hypotonic buffer, and re-pelleted as above. To lyse the nuclei, the pellet was resuspended in 60 μl high-salt buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl₂, 0.2 mM EDTA, 420 mM NaCl,
25% v/v glycerol), vortexed for 30 sec, and samples were then rocked for 1 h at 4°C. The nuclear extract was clarified by pelleting debris for 30 min at 13,000 rpm at 4°C.

Supporting information
S1 File. Tables A-D and Figs A-D. (DOCX)
S2 File. Source data files for Figs 2D, 3C and 6D. (XLSX)

Acknowledgments
We thank Juan Fuxman Bass and Trevor Siggers for comments on the manuscript, and Demetrios Kalaitzidis for helpful discussions.

Author Contributions
Conceptualization: Milad Babaei, Yuekun Liu, Shelly M. Wuerzberger-Davis, Christopher J. DiRusso, Alan T. Yeo, Larisa Kagermazova, Shigeki Miyamoto, Thomas D. Gilmore.
Data curation: Christopher J. DiRusso.
Formal analysis: Milad Babaei, Yuekun Liu, Shelly M. Wuerzberger-Davis, Christopher J. DiRusso.
Funding acquisition: Shigeki Miyamoto, Thomas D. Gilmore.
Investigation: Milad Babaei, Yuekun Liu, Shelly M. Wuerzberger-Davis, Ethan Z. McCaslin, Christopher J. DiRusso, Thomas D. Gilmore.
Methodology: Yuekun Liu, Shelly M. Wuerzberger-Davis, Ethan Z. McCaslin, Christopher J. DiRusso, Alan T. Yeo, Larisa Kagermazova, Thomas D. Gilmore.
Resources: Thomas D. Gilmore.
Supervision: Thomas D. Gilmore.
Writing – original draft: Thomas D. Gilmore.
Writing – review & editing: Milad Babaei, Yuekun Liu, Shelly M. Wuerzberger-Davis, Christopher J. DiRusso, Shigeki Miyamoto, Thomas D. Gilmore.

References
1. Ayoubi TA, Van De Ven WJ. Regulation of gene expression by alternative promoters. FASEB J. 2011; 10:453–60.
2. Davuluri RV, Suzuki Y, Sugano S, Plass C, Huang TH. The functional consequences of alternative promoter use in mammalian genomes. Trends Genet. 2008; 24:167–77. https://doi.org/10.1016/j.tig.2008.01.008 PMID: 18329129
3. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet. 2002; 30:13–9. https://doi.org/10.1038/ng0102-13 PMID: 11753382
4. Xin D, Hu L, Kong X. Alternative promoters influence alternative splicing at the genomic level. PLoS ONE 2008; 3:e2377. https://doi.org/10.1371/journal.pone.0002377 PMID: 18560582
5. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010; 24:2343–64. https://doi.org/10.1101/gad.1973010 PMID: 21041405
6. Zhang J, Manley JL. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov. 2013; 3:1228–37. https://doi.org/10.1158/2159-8290.CD-13-0253 PMID: 24145039
27. Fulco CP, Munschauer M, Anyoha R, Munson G, Grossman SR, Perez EM, et al. Systemic mapping of Fusco F, Paciolla M, Napolitano F, Pescatore A, D’Addario I, Bal E, et al. Genomic architecture at the 24. Galgoéczy P, Rosenthal A, Platzer M. Human–mouse comparative sequence analysis of the NEMO 23. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an 28. Lawhorn IE, Ferreira JP, Wang CL. Evaluation of sgRNA target sites for CRISPR mediated repression 26. Franzè A, Ferrante MF, Fusco F, Santoro E, Martini G, Ursini MV. Molecular anatomy of the human glu- 18. Luedde T, Beraza N, Kotsikori S, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKK 21. Vo Ngoc L, Cassidy CJ, Huang CY, Duttke SHC, Kadonaga JT. The human initiator is a distinct and 20. Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D, et al. Hepatocyte-specific 17. Luedde T, Schwabe RF. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8:108–18. https://doi.org/10.1038/nrgastro.2010.213 PMID: 21293511

16. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene. 2006; 25:6831–43. https://doi.org/10.1038/sj.onc.1209399 PMID: 17072331

15. Maier HJ, Wagner M, Schips TG, Salem HH, Baumann B, Wirth T. Requirement of NEMO/IKK for effective expansion of KRAS-induced precancerous lesions in the pancreas. Oncogene. 2013; 32:2690–5. https://doi.org/10.1038/onc.2012.272 PMID: 22751123

14. Puar YR, Shanmugam MK, Fan L, Arfuso F, Sethi G, Tergaonkar V. Evidence for the involvement of the master transcription factor NF-κB in cancer initiation and progression. Biomedicines. 2018; 6:e82. https://doi.org/10.3390/biomedicines6030082 PMID: 30060453

13. Schmidt-Supprian M, Bloch W, Courtouis G, Addicks K, Israël A, Rajewsky K, et al. NEMO/IKK-deficient mouse model incontinentia pigmenti. Mol Cell. 2000; 5:981–92. https://doi.org/10.1016/s1097-2765(00)80263-4 PMID: 10911992

12. Courtouis G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene. 2006; 25:6831–43. https://doi.org/10.1038/sj.onc.1209399 PMID: 17072331

11. Schaffer R, DeMaria AM, Kagermoser L, Liu Y, Babaei M, Caban-Penix S, et al. A central conserved region of NEMO is required for IKK Β, the first quarter-century: remarkable progress and outstanding questions. Cell Res. 2011; 21:71–85. https://doi.org/10.1038/cr.2010.177 PMID: 21173976

10. Maubach G, Schmadicke AC, Naumann M. NEMO links nuclear factor-κB to human diseases. Trends Mol Med. 2017; 23:1138–55. https://doi.org/10.1016/j.molmed.2017.10.004 PMID: 29128367

9. Sun S-C. Non-canonical NF-κB signaling pathway. Cell Res. 2011; 21:71–85. https://doi.org/10.1038/cr.2010.177 PMID: 21173976

8. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26:203–34. https://doi.org/10.1101/gad.183434.111 PMID: 23209395

7. Vacik T, Raska I. Alternative intronic promoters in development and disease. Protoplasma. 2017; 154:1201–6.

6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883–99. https://doi.org/10.1016/j.cell.2010.01.025 PMID: 20303878

5. Vacik T, Raska I. Alternative intronic promoters in development and disease. Protoplasma. 2017; 154:1201–6.

4. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26:203–34. https://doi.org/10.1101/gad.183434.111 PMID: 23209395

3. Sun S-C. Non-canonical NF-κB signaling pathway. Cell Res. 2011; 21:71–85. https://doi.org/10.1038/cr.2010.177 PMID: 21173976

2. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26:203–34. https://doi.org/10.1101/gad.183434.111 PMID: 23209395

1. Puar YR, Shanmugam MK, Fan L, Arfuso F, Sethi G, Tergaonkar V. Evidence for the involvement of the master transcription factor NF-κB in cancer initiation and progression. Biomedicines. 2018; 6:e82. https://doi.org/10.3390/biomedicines6030082 PMID: 30060453
29. Sanjana NE, Wright J, Zheng K, Shalem O, Fontanillas P, Joung J, et al. High-resolution interrogation of functional elements in the noncoding genome. Science. 2016; 353:1545–9. https://doi.org/10.1126/science.aaf7613 PMID: 27708104

30. Vo Ngoc L, Wang Y-L, Kassavets GA, Kadonaga JT. The punctilious RNA polymerase II core promoter. Genes Dev. 2017; 31:1289–301. https://doi.org/10.1101/gad.303419.117 PMID: 28808065

31. Han Y, Silvano OJ, Christie CK, Cheng AW, Miano JM. CRISPR-Cas9 genome editing of a single regulatory element nearly abolishes target gene expression in mice—brief report. Arterioscler Thromb Vasc Biol. 2015; 35:312–5. https://doi.org/10.1161/ATVBAHA.114.305017 PMID: 25538209

32. Stepanenko A, Andreieva S, Korets K, Mykytenko D, Huleyuk N, Vassetzky Y, et al. Step-wise and punctuated genome evolution drive phenotype changes of tumor cells. Mutat Res. 2015; 771:56–69. https://doi.org/10.1016/j.mrfmmm.2014.12.006 PMID: 25771981

33. Lin YC, Boone M, Meuris L, Lemmens I, Van Roy N, Soete A, et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat Commun. 2014; 5:4767. https://doi.org/10.1038/ncomms5767 PMID: 25182477

34. Schröfelbauer B, Polley S, Behar M, Ghosh G, Hoffman A. NEMO ensures signaling specificity of the pleiotropic IKKβ by directing its kinase activity toward IκBα. Mol Cell. 2012; 47:111–21. https://doi.org/10.1016/j.molcel.2012.04.020 PMID: 22633953

35. Cote S, Gilmore TD, Shaffer R, Weber U, Bollam R, Golden MS, et al. Mutation of nonessential cysteines shows that the NF-κB essential modulator forms a constitutive noncovalent dimer that binds IκB kinase-β with high affinity. Biochemistry. 2013; 52:9141–54. https://doi.org/10.1021/bi401368r PMID: 24266532

36. Salt BH, Niemela JE, Pandey R, Hanson EP, Deering RP, Quinones R, et al. IKBKG (nuclear factor-κB essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J. Allergy Clin Immunol. 2008; 121:976–82. https://doi.org/10.1016/j.jaci.2007.11.014 PMID: 18179816

37. Ku C-L, Picard C, Erods M, Jeurissen A, Bustamante J, Puel A, et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet. 2007; 44:16–23. https://doi.org/10.1136/jmg.2006.044446 PMID: 16950813

38. Kawai T, Nishikomori R, Izawa K, Murata Y, Tanaka N, Sakai H, et al. Frequent somatic mosaicism of NEMO in T cells of patients with X-linked anhidrotic ectodermal dysplasia with immunodeficiency. Blood. 2012; 119:5458–66. https://doi.org/10.1182/blood-2011-05-354167 PMID: 22517901

39. Fusco F, Bardaro T, Fimiani G, Mercadante V, Miano MG, Falco G, et al. Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-κB activation. Hum Mol Genet. 2004; 13:1763–73. https://doi.org/10.1093/hmg/ddh192 PMID: 15229184

40. Gilmore TD, Garbati MR. Inhibition of NF-κB signaling as a strategy in disease therapy. Curr Top Microbiol Immunol. 2011; 349:245–63. https://doi.org/10.1007/82_2010_105 PMID: 21113699

41. Glass Z, Lee M, Li Y, Xu Q. Engineering the delivery system for CRISPR-based genome editing. Trends Biotech. 2018; 36:173–85.

42. Pan Y, Yang Y, Luan X, Liu X, Li X, Yang J, et al. Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform. Science Adv. 2019; 5:eaav7199.

43. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2018; 171:481–94.

44. Herscovi tch M, Comb W, Ennis T, Coleman K, Yong S, Armstead B, et al. Intermolecular disulfide bond formation in the NEMO dimer requires Cys54 and Cys347. Biochem Biophys Res Commun. 2009; 367:103–8.

45. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014; 11:783–4. https://doi.org/10.1038/nmeth.3047 PMID: 25075903

46. Miyamoto S, Seufzer BJ, Shumway SD. Novel IκBα proteolytic pathway in WEHI231 immature B cells. Mol Cell Biol. 1998; 18:19–29. https://doi.org/10.1128/mcb.18.1.19 PMID: 9418849

47. Jackson SS, Miyamoto S. Dissecting NF-κB signaling induced by genotoxic agents via genetic complementation of NEMO-deficient 1.3E2 cells. Methods Mol Biol. 2015; 1280:197–215. https://doi.org/10.1007/978-1-4939-2422-6_11 PMID: 25736750